MyFinsight
Home
Blog
About
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Net proceeds from exercise of wa...
Net proceeds from notes payable
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net loss
License payments
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-8,923,846
-26,609,695
-5,534,069
-4,996,656
Stock-based compensation expense
3,560,791
3,526,710
3,956,050
2,298,132
Amortization of in-process research and development
1,720,312
1,720,312
573,438
-
Amortization of deferred financing costs
179,492
-
-
-
Deferred income tax expense
-107,347
-231,210
264,240
264,240
Accounts receivable, net of allowances
-392,820
-2,970,056
4,049,111
-
Inventory
-33,645
20,248
352,649
3,709,006
Prepaid expenses
-221,107
-110,553
3,431,660
-
Accounts payable
-1,567,723
-1,563,661
-2,787,784
4,567,265
Accrued expenses
16,047
19,538,657
425,792
-4,365,430
Due to related party
1,764,072
-3,273,092
1,980,807
2,049,409
Net cash (used in) provided by operating activities
-2,710,630
-3,831,618
-7,354,946
-5,492,046
License payments
2,000,000
600,000
4,400,000
5,750,000
Net cash used in investing activities
-2,000,000
-600,000
-4,400,000
-5,750,000
Net proceeds from notes payable
9,635,000
-
-
-
Net proceeds from exercise of warrants and pre-funded warrants
9,730,818
-
-
-
Deferred financing costs
723,299
169,252
-
-
Net proceeds from issuance of common stock
-818
-61,947
15,125,489
15,166,842
Net cash provided by financing activities
18,641,701
-231,199
15,125,489
15,166,842
Net change in cash and cash equivalents
13,931,071
-4,662,817
3,370,543
3,924,796
Cash and cash equivalents beginning of period
-
7,295,451
3,924,908
112
Cash and cash equivalents end of period
16,563,705
2,632,634
7,295,451
3,924,908
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net proceeds from
exercise of warrants and...
$9,730,818
Net proceeds from
notes payable
$9,635,000
Net cash provided by
financing activities
$18,641,701
Canceled cashflow
$724,117
Net change in cash
and cash...
$13,931,071
Canceled cashflow
$4,710,630
Deferred financing costs
$723,299
Net proceeds from
issuance of common stock
-$818
Stock-based compensation
expense
$3,560,791
(-40.87%↓ Y/Y)
Due to related party
$1,764,072
(-74.34%↓ Y/Y)
Amortization of in-process
research and development
$1,720,312
Accounts receivable, net
of allowances
-$392,820
Prepaid expenses
-$221,107
(86.18%↑ Y/Y)
Amortization of deferred
financing costs
$179,492
Inventory
-$33,645
(-100.38%↓ Y/Y)
Accrued expenses
$16,047
(-99.81%↓ Y/Y)
Net cash (used in)
provided by operating...
-$2,710,630
Net cash used in
investing activities
-$2,000,000
Canceled cashflow
$7,888,286
Net loss
-$8,923,846
(54.85%↑ Y/Y)
License payments
$2,000,000
Accounts payable
-$1,567,723
(-131.63%↓ Y/Y)
Deferred income tax
expense
-$107,347
(-113.54%↓ Y/Y)
Buy us a coffee